The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: A double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate

Journal of the Neurological Sciences

Volumn 320, Issue 1-2, 2012, Pages 121-126

  Drijgers, Rosa L ^a,b   Verhey, Frans R J ^a,b   Tissingh, Gerrit ^c   Van Domburg, Peter H M F ^c   Aalten, Pauline ^a,b   Leentjens, Albert F G ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Alzheimer Center Limburg   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

Author keywords

Cognition; Dopamine; Methylphenidate; Mood; Motivation; Parkinson; Pramipexole

Indexed keywords

METHYLPHENIDATE; PLACEBO; PRAMIPEXOLE;

ADULT; ANGER; ANHEDONIA; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIZZINESS; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; MALE; MOOD; MOTIVATION; NAUSEA; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STRESS;

AFFECT; AGED; BENZOTHIAZOLES; COGNITION; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DOPAMINERGIC NEURONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; MOTIVATION; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REACTION TIME;

EID: 84864601741     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.07.015     Document Type: Article

References (47)

1. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2 2003 197 211
2. C. Delaville, P.D. Deurwaerdere, and A. Benazzouz Noradrenaline and Parkinson's disease Front Syst Neurosci 5 31 2011 [Epud ahead of print]
3. M.C. Rodriquez-Oroz, M. Jahanshahi, P. Krack, I. Litvan, R. Macias, and E. Bezard Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms Lancet Neurol 8 2009 1128 1139
4. J.S.A.M. Reijnders, U. Ehrt, W.E.J. Weber, D. Aarsland, and A.F.G. Leentjens A systematic review of prevalence studies of depression in Parkinson's disease Mov Disord 23 2008 183 189
5. K.R. Bogart Is apathy a valid and meaningful symptom or syndrome in Parkinson's disease? A critical review Health Psychol 30 4 2011 386 400
6. P. Barone, A. Antonini, C. Colosimo, R. Marconi, L. Morgante, and T.P. Avarello The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease Mov Disord 24 11 2009 1641 1649
7. H. Lavretsky, M. Ballmaier, D. Pham, A. Toga, and A. Kumar Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study Am J Geriatr Psychiatry 15 5 2007 386 394
8. J.S.A.M. Reijnders, B. Scholtissen, W.E.J. Weber, P. Aalten, F.R.J. Verhey, and A.F.G. Leentjens Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry Mov Disord 25 14 2010 2318 2325
9. L.C. Butterfield, C.R. Cimino, L.E. Oelke, R.A. Hauser, and J. Sanchez-Ramos The independent influence of apathy and depression on cognitive functioning in Parkinson's disease Neuropsychology 24 6 2010 721 730
10. G.C. Pluck, and R.G. Brown Apathy in Parkinson's disease J Neurol Neurosurg Psychiatry 73 6 Dec 2002 636 642
11. K.F. Pedersen, G. Alves, K. Bronnick, D. Aarsland, O. Tysnes, and J.P. Larsen Apathy in drug-naive patients with incident Parkinson's disease: the Norwegian ParkWest study J Neurol 257 2010 217 223
12. K. Chaudhuri, and A. Schapira Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol 8 5 2009 464 474
13. A. Evans, A. Lawrence, and A. Lees Changes in psychomotor effects of l-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease J Neurol Neurosurg Psychiatry 80 2009 267 272
14. A.F.G. Leentjens, J. Koester, B. Fruh, D.T.S. Shephard, P. Barone, and J.J.G. Houben The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo controlled studies Clin Ther 31 1 2009 89 98
15. V. Czernecki, B. Pillon, J.L. Houeto, J.B. Pochon, R. Levy, and B. Dubois Motivation, reward, and Parkinson's disease: influence of dopatherapy Neuropsychologia 40 13 2002 2257 2267
16. M. Menza, R.D. Dobkin, H. Marin, M.H. Mark, M. Gara, and S. Buyske A controlled trial of antidepressants in patients with Parkinson's disease and depression Neurology 72 10 2009
17. D. Devos, K. Dujardin, I. Poirot, C. Moreau, O. Cottencin, and P. thomas Comparison of desipramine and citalopram treatments of depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study Mov Disord 23 6 2008 850 857
18. R.L. Drijgers, P. Aalten, A. Winogrodzka, F.R.J. Verhey, and A.F.G. Leentjens Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review Dement Geriatr Cogn Disord 28 1 2009 13 22
19. M.C. De Rijk, W.A. Rocca, D.W. Anderson, M.O. Melcon, M.M.B. Breteler, and D.M. Maraganore A population perspective on diagnostic criteria for Parkinson's disease Neurology 48 1997 1277 1281
20. M.F. Folstein, S.E. Folstein, and P.R. McHugh Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 3 1975 189 198
21. J. Jolles, P.J. Houx, M.P.J. Van Boxtel, and R.W.H.M. Ponds The Maastricht aging study; determinants of cognitive aging 1995 Neuropsych Publishers Maastricht
22. Anonymous The European Public Assessment Report (EPAR) for Sifrol 2009
23. Anonymous IB-tekst Ritalin 2010 Novartis Arnhem
24. S. Fahn, and R.L. Elton Unified Parkinson's disease rating scale 1987 McMillan Health Care New Jersey
25. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
26. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 Feb 1960 56 62
27. P. Sockeel, K. Dujardin, D. Devos, C. Deneve, A. Destee, and L. Defebvre The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease J Neurol Neurosurg Psychiatry 77 5 May 2006 579 584
28. R.S. Marin, R.C. Biedrzycki, and S. Firinciogullari Reliability and validity of the Apathy Evaluation Scale Psychiatry Res 38 2 Aug 1991 143 162
29. J.L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi, and J. Gornbein The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology 44 1994 2308 2314
30. D. McNair, M. Lorr, and L. Droppleman Manual for the profile of mood states 1971 Educational and Industrial Testing Service San Diego
31. B. Scholtissen, F.R. Verhey, J.J. Adam, and A.F.G. Leentjens Challenging the serotonergic system in Parkinson's disease patients: effects on cognition, memory, motor performance and mood Clin Neuropharmacol 29 5 2006 276 285
32. R.P. Snaith, M. Hamilton, S. Morley, A. Humayan, D. Hargreaves, and P. Trigwell A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale Br J Psychiatry 167 1 Jul 1995 99 103
33. I.H.A. Franken, E. Rassin, and P. Muris The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS) J Affect Disord 99 2007 83 89
34. B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon The FAB: a Frontal Assessment Battery at bedside Neurology 55 11 2000 1621 1626
35. C.F. Lima, L.P. Meireles, R. Fonseca, S.L. Castro, and C. Garett The Frontal Assessment Battery (FAB) in Parkinson's disease and correlations with formal measures of executive functioning J Neurol 255 2008 1756 1761
36. W. Van der Elst, M.P. van Boxtel, G.J. van Breukelen, and J. Jolles The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex J Clin Exp Neuropsychol 28 6 2006 998 1009
37. D.A. Mendonca, K. Menezes, and M.S. Jog Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial Mov Disord 22 14 2007 2070 2076
38. C.G. Goetz, W. Poewe, O. Rascol, C. Sampaio, G.T. Stebbins, and C. Counsell Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations Mov Disord 19 9 2004 1020 1028
39. A.F.G. Leentjens, F.R. Verhey, R. Lousberg, H. Spitsbergen, and F.W. Wilmink The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease Int J Geriatr Psychiatry 15 7 2000 644 649
40. P. Navan, L.J. Findley, J.A.R. Jeffs, R.K.B. Pearce, and P.G. Bain Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor Mov Disord 18 11 2003 1324 1331
41. A. Hamidovic, U.J. kang, and H. de Wit Effect of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers J Clin Psychopharmacol 28 1 2008 45 51
42. E. Auriel, J.M. Hausdorff, and N. Giladi Methylphenidate for the treatment of Parkinson disease and other neurological disorders Clin Neuropharmacol 32 2 2009 75 81
43. A. Chatterjee, and S. Fahn Methylphenidate treats apathy in Parkinson's disease J Neuropsychiatry Clin Neurosci 14 4 Fall 2002 461 462
44. R. Camicioli, E. Lea, J.G. Nutt, G. Sexton, and B.S. Oken Methylphenidate increases the motor effects of l-dopa in Parkinson's disease: a pilot study Clin Neuropharmacol 24 4 2001 208 213
45. A. Costa, A. Peppe, G. Dell'Agnello, C. Caltagirone, and G.A. Carlesimo Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory Neuropsychologia 47 2009 1374 1381
46. L. Brusa, A. Bassi, A. Stefani, M. Pierantozzi, A. Peppe, and M.D. Caramia Pramipexole in comparison to l-dopa: a neuropsychological study J Neural Transm 110 2003 373 380
47. M. Relja, and N. Klepac A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease J Neurol Sci 248 2006 251 254